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Background
Challenges of “standardisation” and “individualisation”
have always been characteristic for medical services. In
terms of individualisation, the best possible individual
care is the ethical imperative of medicine, and it is a
good right of any patient to receive it. However, in terms
of standardisation, all the available treatments are based
on guideline recommendations derived from large multi-
centre trials with many thousands of patients involved.
In the most optimal way, the standardisation and indi-
vidualisation should go hand-in-hand, in order to iden-
tify the right patient treating him/her with the right
medication and the right dose at the right time point!
Further, in paradigm and anticipation, there is a big
discrepancy between “disease care” and “health care”
which dramatically impacts ethical and economical as-
pects of medical services.
Several approaches have been suggested in ancient
and modern medicine to conduct medical services in a
possibly optimal way. What is the difference amongst
all of them and how big is the potential beyond corre-
sponding approach to satisfy the needs of the individ-
ual, the patient, professional groups involved and
society at large?
On behalf of the “European Association for Predictive,
Preventive and Personalised Medicine,” the dedicated
EPMA working group provides a deep analysis in the issue
followed by the expert recommendations considering the
multifaceted aspects of both “disease care” and “health
care” practices including ethics and economy, life quality
of individuals and patients, interests of professional groups
involved, benefits of subpopulations, health care system(s)
and society as a whole.
Traditional, complementary and alternative
medicine (TCAM)
TCAM, also called “integrative medicine,” is consid-
ered as an amorphous concept comprising a range of
ancient, long-standing but still evolving treatment
approaches being practised mainly in their countries of
origin as well as in countries into which corresponding
expertise has been “imported” [1]. TCAM refers to
health practices, approaches, knowledge and beliefs
incorporating plant-, animal- and mineral-based medicines,
spiritual therapies, manual techniques and exercise
(e.g. in form of acupuncture, dietary therapy, herbal
medicine, moxibuston, TaiJi, Ayurveda, amongst
others) applied singularly or in combination to diag-
nose, treat and prevent illnesses or maintain well-
being [2]. However, the educational level of the doctor
is critical for the quality of TCAM that depends on
the national/local curricula varying substantially from
country to country and, therefore, may not be ad-
equate enough to fully realise potential benefits of
various forms of TCAM modalities. TCAM approaches
are frequently considered as being non-evidence based
[3]. Further deficiencies arise from evident philosophical
and religious differences as well as some cultural barriers
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between the countries of origin and countries into which
TCAM is “imported” [1]. Nevertheless, in addition to the
conventional medicine, TCAM is getting more and more
popular and well-pursued in Western countries. From
view point of predictive and preventive medicine, TCAM
provides a unique expertise for recognising the so-called
suboptimal health conditions before a clinical manifest-
ation of severe pathologies [3–5]. These global trends
make particularly attractive consideration regarding
innovative hybrid approaches which would utilise advan-
tages of both TCAM and modern medicine and, therefore,
benefiting patients and enriching the spectrum of tools
and overall expertise of the dedicated professional groups
assuring the reproducibility of TCAM technologies and
outcomes [6]. However, those approaches are currently
underdeveloped and require additional major efforts in
terms of multi-professional collaboration, scientific and
technological discoveries and extensive financial support.
Person-centred medicine
The main idea of the person-centred medicine is to
promote health and, therefore, reduce disease burden. In
this concept, any health condition is considered as an
individual state of physical, mental, social and spiritual
well-being. Contextually, health care approaches are
prioritised by person-centred medicine compared to a
disease care. Humanistic interpretation of medicine is
characteristic including the articulation of science,
enhanced understanding of positive health versus illness,
emphasised personalisation of all medical services as
well as strong patient empowerment and essential respon-
sibility of every person, at individual and community
levels. “All for one and one for all”—a smart but perhaps a
bit naive slogan introduced by the Three Musketeers fits
well to the philosophy of the person-centred medicine.
Therefore, a realisation of those ideas demands clear
definitions and validated strategies to reach a reasonable
level of maturity in health care [7].
Individualised medicine
A great strength of individualised medicine (IM) is to
provide a holistic and integrative approach for medical
care. IM comprises curative, rehabilitative and prevent-
ive examination as well as treatment methods custo-
mised for the individual and the patient [8]. IM well
recognises a multidimensional interaction of internal
and external risk factors, genetic background, age,
gender, environmental risk factors, lifestyle, culture and
beliefs as well as social status in the overall predispos-
ition of individuals to specific diseases, the disease
development, the natural course of disease and the
response to therapeutic intervention. These factors vary
from individual to individual. Contextually, IM aims to
categorise patients into clinically relevant subgroups
(that is the content of the “Stratified medicine” —see
below). Hence, at the heart of the concept of IM is a
stratification that “individualises” a one-size-fits-all
standardised intervention into a group-specific inter-
vention. Less clear concepts and approaches are
provided by IM towards “predictive and preventive
medicine”—see below.
Stratified medicine
Stratified medicine means looking at large groups of
affected individuals (e.g. cancer patients) to try and find
ways of predicting which treatments/patient sub-types
are likely to respond to. Specifically in cancer, it involves
looking in detail at the cancer cells and their genetic
make-up. The purpose of the approach is to find out
which treatment algorithms are more likely to work [9].
Patient stratification is one step towards individualised
patient treatments and so-called “personalised medicine”—
see below.
Personalised medicine
The term “personalised medicine” is the keyword to
refer to the best possible, most optimal and innovative
medical approaches in the early twenty-first century, to
justify grant applications and to receive dedicated bud-
gets. However, in order to make anticipation by persona-
lised medicine as realistic as possible, this term should
be pragmatically sub-divided into its clear subcategories,
namely “semi-personalised” versus “true personalised” as
it has been discussed and published elsewhere in scien-
tific literature [10].
“Semi-personalised medicine” compromises between
standardisation and individualisation in medicine, the
first step of which is the stratification of big patient-
groups according to certain well-known characteristics
(e.g. specific biological characteristics of the tumour). In
the next step, individual patients within the group are
treated according to the algorithms adapted to the entire
stratified group. Consequently, the treatment efficacy
varies from patient to patient within the group, since a
limited number of characteristics in common is consid-
ered by the treatment algorithm; all other individual
characteristics are not taken into account but may
sufficiently impact individual outcomes.
“True personalised medicine” is based on the “individ-
ual patient profile” (see “Predictive, preventive and
personalised medicine (PPPM)” section) directing to a
tailored therapy that maximises the efficacy for that one
patient in particular.
However, a disadvantage of “personalised medicine” is
that its contents are adapted to the needs of disease care
for treatments of diseased individuals and individual
patient cohorts but not for health care of individuals to
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maintain in a good mental and physical shape avoiding
clinical manifestation of diseases.
Precision medicine
The terms precision, personalised and individualised
medicines are often used interchangeably [11]. Precision
medicine is a concept of therapeutic and preventive
modality for disease that takes into account individual
variability in genes, environment and lifestyle. It refers
to the tailoring of medical treatment to the individual
characteristics of each patient [12]. Precision medicine is
considered a relatively new approach in disease and
health care, although it has been around for a while and
has limited application in certain fields of medicine such
as blood transfusion and organ transplantation. Further,
precision medicine faces a number of serious challenges
that need to be addressed [13–18] as summarised below.
a) Knowledge gap: Extensive and costly long-term
education is required for all health care system
authorities, physicians and participants to fully
understand the dynamic and potential objectives
of precision medicine.
b) Authority and interpretation: Even for the field
specialists, an interpretation of DNA data for
individual health outcomes remains sophisticated
and the problem of interpretability continues to
grow. Consequently, many doctors are simply not
able to make sense of genetic tests and to
communicate the results accurately to their patients.
c) Data storage: Gene sequencing of an individual
produces massive amounts of data. The sequencing
of thousands, if not millions, of people will produce
unimaginable amount of data. How will we store
the data and effectively analyse to derive useful
information and to interpret the data?
d) Pathogenic mechanism: Many diseases have complex
and multifactorial pathogenic mechanisms which
would make it very difficult to identify a specific
gene responsible for their manifestations.
e) Most technologies and equipment required for
effective implementation of precision medicine are
still in embryonic stages.
f ) Privacy/security: Cyberattack is increasingly a major
hurdle to maintaining privacy and security for all
particularly given the current state of world affairs.
Such valid concerns are already well-recognised for
economic, energy and defence sectors across the
globe. Precision medicine relies on massive public
and personal data requiring sophisticated and
extensive infrastructure and technology. Thus,
vulnerability due to breach of security and privacy
violation could have devastating consequences for
the successful implementation of precision medicine
[19] and data misusing, e.g. for economic and
political purposes with a consequent discrimination
of affected individuals and even (sub)populations
involved in the database containing sensitive genetic
information and family history amongst others.
g) Coordination and policies: For precision medicine to
have its greatest impact, federal and private health
insurance companies have no option but to become
comfortable with value-based drug pricing.
h) Variability of phenotypic features in population: It is
difficult, if not impossible, to detect, decipher and
utilise phenotypic characteristics of every individual
as indicators for diseases as seems to be proposed
by precision medicine.
i) Data relevance: The usefulness of data gathered
from smaller groups may not be sufficient to make
larger population health recommendations.
j) Culture: Prevention of abuse of information for
unintended purposes such as screening potential
partners and denying insurance coverage is a serious
concern. How will this affect the culture? Will we be
cultivating a different kind of racism, on a genetic
basis?
k) Ownership: Who will have ownership of the data?
Will it be the government? It is noteworthy that
the FDA has blocked companies from allowing
individuals to have access to their own genetic
information. Will this change as part of the new
initiative?
l) Compliance: There is no binding protocol to
guarantee that all individuals would follow the
recommendations made by precision medicine so
the diseases could be prevented, controlled or cured.
m)Drug/device industry: Genetic research and
development of treatment options have been very
promising and productive in the private sector. How
will government involvement affect research? Will
governmental agencies work cooperatively with
them or competitively?
n) Diversion from overarching goals of health care
system: The focus and concentration of human
and financial resources on precision medicine
may divert attention and concerns of health care
system from efforts to remedy the foundational
causes of ill health such as poverty, obesity and
education.
o) Health care costs: Genetic mapping of a population,
and analyses of data, securing the information and
deriving treatment recommendation are very costly
which can be readily hampered by budgetary
constraints of high dynamic economies. Further, the
costs of converting the intellectual capital to
therapeutic modalities must also be taken into
account and built into the health care system.
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p) Finally, it is noteworthy that the concept of
precision medicine may be a repackaging of the
ideals advanced by the human genome project in
2000. The hope was to identify genetic markers for
the ultimate objective of developing novel
biomarkers and overcome perceived therapeutic
deficiencies and overcome the pressing issue of
non-responders. However, this noble objective has
not been fully materialised yet, leading one to the
question: Is precision medicine “old vine in a new
bottle”?
In conclusion, precision medicine could potentially
improve preventive methods and therapeutic options.
However, a number of challenges remain as alluded to
above—see also the cartoon in Fig. 1. Precision medicine
will have to demonstrate consistency, coherence, com-
prehensiveness, clarity and relevance to every individual
and community impacted by these developments in
medical research and treatment. Will precision medicine
deliver all that it promises? With increasing shrinking of
financial resources, is it wise to invest millions of dollars/
euros in an approach for which its risks versus benefits
ratio does not ring a satisfactory bell? Perhaps, stake-
holders and authorities would be better off to further
invest and focus on the already established concepts of
“predictive, preventive and personalised medicine.”
Predictive, preventive and personalised medicine
(PPPM)
The paradigm shift from “unPPPM” to “PPPM”
The above described great plurality of approaches indi-
cates a broad understanding of clear deficits which do
exist in currently applied medical services and attempts
of diverse professional groups to remedy the deficits. On
the other hand, there is an increasing level of under-
standing that persisting deficits carry a fundamental
character and, therefore, cannot be solved by superficial
modifications of health care systems facilitating individual
technologies such as “cancer genomics” by “precision
medicine.”
Global deficits are well-defined and described else-
where as unpredictable, unpreventable and impersonal
medicine [20, 21]. It is evident that a paradigm shift is
needed to move from “reactive” to “predictive, prevent-
ive and personalised medicine” as a new philosophy
Fig. 1 “Precision” itself does not guarantee for better understanding of an issue. An old wise dictum adopted by all European cultures/languages
warns—one cannot see the forest for the trees. Hence, technologically driven higher resolution of individual elements does not automatically mean
that you can better recognise the complex problem which you are looking for, particularly when the zoomed element (the tree) is prioritised
and/or pulled out from the overall context or zooming itself makes the complete picture (the forest/multifactorial issue) unreadable. Contextually,
better understanding of the complexity in medicine is not guaranteed by “precision medicine” itself. Advanced health care demands a close
cooperation between all issue-related fields, integration of multidisciplinary knowledge and innovative technologies based on long-term strategies
and concepts considering interests of patients, professionals and society at large
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covering both “health care” and “disease care”, promot-
ing an integrated approach combining advantages of in-
dividual bio/medical fields and technologies and
consolidating a multi-professional collaboration.
New paradigm has been created by the EPMA experts
as published earlier [22]—see Fig. 2.
Particular emphasis on ethics in PPPM
Sometimes, we, living in the XXI century, forget what
was taught when the first universities were established at
the birth of XI century: “Never discuss about names,”
“Never enter an onomatomachia”, that is, never enter a
fight (in ancient Greek, μάχη, máchi) about names (in
ancient Greek, όνoμα, ónoma). Sometimes, the meanings
of the names “person-centred medicine,” “individualised
medicine,” “stratified medicine,” “precision medicine,”
“personalised medicine,” etc. are not so sharp; some-
times, they intersect, but it is not clear until which
point.
This is not a void and abstract “philosophical” ques-
tion (actually, over the centuries and the millennia, the
philosophers never thought that a question of names
was a genuine philosophical question). This is a matter
of money, a matter of grants, and a matter of power.
This means that the onomatomachia now occurring in
the field of contemporary biomedicine is actually a war
for money and for power. But the citizens, in particular
a subset of them, that is, the diseased citizens, are totally
disinterested about it, even if, unfortunately, negative
side effects of this war affect them. Citizens are
interested in a personalised care, whatever this could
precisely mean [23].
This means that beside a scientifically well-founded
medical approach facing their unique potential or actual
disease, they wish that their unique biography could be
taken into account as well. Yet let us put aside for a
while the biographical part (i.e. the age, gender, cultural,
ethnic, religious, socio-economic diversity) of an actual
or potential patient, even if we know, from epigenomics,
that patients’ lifestyles and the environments in which
they live are extremely impacting their quality of life and
their actual or potential diseases. Let us focus on the
“medical” part.
A citizen with an actual or potential disease wants a
medicine in which he/she is at the centre, a medicine
which is tailored on his/her polymorphism, a medicine
which is able to provide him/her with the right therapy,
in the right dose, at the right moment, for the right
period of time. But he/she also wants a medicine which
is able to predict and prevent possible diseases. He/she
is not interested in the way in which this kind of medi-
cine is called. But he/she is interested in understanding
why it is called in that way, in order to appreciate its
potential ability to restore health. And this is the real
advantage of speaking in terms of predictive, preventive
and personalised medicine: the actual or potential pa-
tient understands what is going on!
Nevertheless, there is something more. The PPPM
lends itself to an over-arching umbrella under which the
main ethical issues of contemporary biomedicine could
be positively tackled. Certainly, a predictive and prevent-
ive approach could imply several ethical problems
linked, for example, to overdiagnosis and overtreatment,
detection of incidental findings, psychological burden
Fig. 2 Paradigm shift from “reactive” to “predictive, preventive and personalised medicine”
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and severe existential choices connected with the know-
ledge of the probability of a possible disease affecting us
or our offspring and lineages, or connected with our
reproductive choices, etc. Contextually, PPPM plays a
crucial role as the optimal medical partner of a serious
ethical counselling (and here, the patient’s biography
plays its main role) offered to actual or potential indi-
vidual patients, in order to empower them to make an
infirmed choice about the diagnostic, surveillance or
therapeutic path to take, especially whenever these paths
intersect ethical or existential problematic situations that
they have to solve [24].
Towards scientific excellence and practical PPPM
implementation: special professional focuses by the EPMA
This subsection is based on the well-elaborated PPPM
aspects evidently advancing medical sciences and health
care. Corresponding professional statements have been
approved by the association within the fundamental
document resulting from the EPMA Summit 2014 under
the auspices of the presidency of Italy in the EU [6].
PPPM in cancer: the key questions puzzling medical
sciences and advancing health care
The majority of people may carry hardly detectable
micro- and asymptomatic tumour lesions as it has been
demonstrated by a series of detailed autopsy studies.
However, those lesions do not necessarily progress into
clinically manifest oncologic diseases. Furthermore, there
is a phenomenon of the so-called metastatic inefficiency,
due to less than 1 % of all disseminated and circulated
tumour cells which have a potential to form secondary
and distanced tumours (metastatic disease) [25]. Con-
textually, the key question puzzling modern predictive,
preventive and personalised medicine in oncology is how
to predict and effectively protect against clinical manifest-
ation of the disease by distinguishing between “silent” car-
riers of tumour lesions and patients who are predisposed
to a disease development and progression. The clue might
be a “fertile” microenvironment that effectively supports
the tumorigenesis, tumour invasiveness and aggressive
metastatic disease [26]. The mechanisms “fertilising” the
microenvironment for the cancer advancement are
well-addressed by innovative PPPM strategies in can-
cer [26–29].
PPPM advancements in CVD management: a global health
issue
Currently, the CVD-related health burden is the most
severe in developed countries and becomes overgrown
in developing countries as well. The main reason for that
is that the chronic disease stages, multifactorial diseases
and comorbidities are not adequately addressed, since
they do not follow the PPPM principles in currently
practised health care systems [30]. An advanced CVD
management is needed at both population and individual
levels considering complex cardiovascular risk factors,
co-morbidities, individualised patient profiles, optimised
screening programmes and innovative preventive strat-
egies. Chronic suboptimal health conditions such as pri-
mary vascular dysregulation (Flammer syndrome) may
be relevant for a number of predispositions and severe
pathologies with poor outcomes [31–33]. Consequently,
the promotion of PPPM in CVD management is a global
health issue [34–36].
Global epidemic of diabetes type 2—twenty-first century
disaster and PPPM solutions
Current epidemiologic studies report about over 400
million of diabetes mellitus (DM) diseased patients
worldwide. A big portion of DM cases remains undiag-
nosed. More and more teenagers are affected by DM
type 2. The global epidemic of DM type 2 places an
alarming burden on health care systems. The conse-
quent challenges and costs overload both developed and
developing countries and economies. An effective imple-
mentation of PPPM concepts to diabetes care is due
long ago. EPMA emphasises the need to address the
all-encompassing complex approach for population
screening, primary, secondary and tertiary care bene-
fiting non-diseased individuals, predisposed subgroups
and affected patient cohorts including those with
comorbid pathologies such as CVD, cancer, and
neurological, neuropsychiatric and neurodegenerative
diseases (NNND) amongst others [6, 35, 37, 38].
PPPM advancing the comprehensive area of NNND
In a very few years, NNND are predicted to represent
the majority of socially and economically devastating
disorders and diseases. Multifactorial physical and cogni-
tive disability of NNND-affected patient cohorts results
from individual interplay of genetic, epigenetic and
environmental risk factors. Contextually, the compre-
hensive area of NNND demands new strategies which
would create a robust platform for the cost-effective
medicine of future NNND management [39–42]. Conse-
quently, the advanced PPPM concepts do place particu-
lar emphasis on primary prevention by the identification
of predisposed individuals, improved patient stratifica-
tion and treatments tailored to the person [6]. However,
new regulations and innovative reimbursement pro-
grammes are mandatory to prompt an effective imple-
mentation of the above listed concepts.
Rare disease (RD) management: proof-of-principles for
personalised medical care
Although an entire spectrum of RDs affects many mil-
lions of people worldwide (e.g. in Europe, there are at
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least 30 million patients), currently, no appropriate diag-
nostic and treatment approaches are available for most
of afflicted with individual RDs. The majority of RDs can
be diagnosed in prenatal and early postnatal periods.
Due to the genetic background of most RD pathologies,
the multimodal diagnostic and treatment approaches
propagated by PPPM are instrumental for personalisa-
tion of RD management [43].
Ancient medical traditions “reinforced” by innovative PPPM
concepts
PPPM creates a unique platform for “reinforcing” trad-
itional approaches of the ancient medicines (TCAM).
PPPM-TCAM hybrid demonstrates a great potential in
person-centred and participatory medicine, disease pre-
diction in individuals with suboptimal health condition,
targeted prevention and individualised treatments. If
properly designed, PPPM-TCAM approach may be of
particular value for health care systems that empowers
communities and individuals [3, 44].
Application of PPPM to the pain management benefiting all
medical fields
Pain management is the central issue for a variety of
syndromes, acute, chronic and systemic disorders. Pain
diagnostics and treatment are highly individual involved
in a wide spectrum of suboptimal health conditions,
early and advanced stages of developing pathologies and
collateral diseases such as CVD, NNND, diabetes, and
cancer. Application of PPPM concepts to advanced
pain management demands multidisciplinary expertise
considered in the context of improved health care
economy and policy and direct benefits to the patient
[45–47].
Impacts of the oral and dental health: novelty by PPPM
concepts
On the one hand, dental diseases are frequently caused
by systemic disorders such as diabetes mellitus. On the
other hand, dental and oral pathologies are both early
indicators and risk factors for a variety of multifactorial
diseases. This includes pre-term birth, a spectrum of
vascular pathologies, stroke, heart and lung disease, dia-
betes mellitus with comorbidities, some types of cancer,
neurological disorders and several mental disorders such
as depression, anxiety, anorexia and even bulimia.
Therefore, investigation of the cause-and-effect relation-
ships between oral and dental diseases on the one hand
and multifactorial systemic disorders on the other hand
is a prerequisite for predictive, preventive and persona-
lised medicine in the multidisciplinary fields of dental
and oral health care [48–52].
Environmental factors in a sensitive balance between health
and disease
There is a highly sensitive interplay between a genetic
component, epigenetic regulations and environmental
factors that determines a sensitive balance between
health and disease in individuals. Unfortunately, envir-
onment is still a largely neglected topic in health care.
PPPM approach aims to develop an appropriate know-
ledge and technological skills for promoting affordable
strategies in the emerging fields of environmental risk
factors, epidemiology, healthy lifestyle, individualised
nutrition, food technology and culture in a framework of
cost-effective health care [29, 47, 53–55].
Robust PPPM platform to advance regenerative medicine
Prediction and personalisation in regenerative medicine
are prerequisites for improved individual outcomes. Hence,
in order to optimally match the donor to recipient and
assess individual risks, a successful transplantation requires
valid pathology-specific pre- and post-transplantation bio-
marker panels tailored to the individual. Long waiting lists
of patients worldwide reflect major problems and current
deficits, which require PPPM-related solutions advancing
this medical area on the global scale [6]. Individual compo-
nents of the overall management leading to substantially
increased allograft survival and decreased patient morbid-
ity are an improved donor-recipient matching, individual
risk assessment for chronic allograft damage, predic-
tion of graft accommodation and creation of personalised
immunosuppressive algorithms.
Body culture and sports medicine (BCSP) effectively
promoted by PPPM
PPPM strategies in BCSP are based on optimisation of
the relationship between individual genetic predispositions
and modifiable risk factors (nutrients, physical activity,
lifestyle, etc.). Therefore, the main tools are individualised
physical exercises and therapy algorithms, healthy balance
between body tension and relaxation, optimised sleep
algorithms according to individual circadian rhythm, in-
novative rehabilitation approaches, amongst others. Anti-
doping control and effective measures are mandatory for
PPPM implementation in advanced BCSP. High-quality
research based on measurable effects utilising multilevel
biomarker panels is effectively promoted by PPPM in
BCSP with a particular focus on individually tailored inter-
ventions [56–59].
Translational medicine: a powerful bridge between PPPM
science and implementation
There are many scientific fields which, on a daily basis,
provide a great knowledge potentially useful for advanced
medical services. However, a number of scientific articles
and valuable patents remain unused. The “bottleneck”
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between the sciences and application has many reasons
including economic circumstances and missing political
regulations. In order to effectively promote the transla-
tional medicine as the “catalyser” for practical implemen-
tation of the accumulated scientific achievements, EPMA
creates a robust platform for an effective dialogue between
PPPM relevant professional groups on the one side, and
industry and policy-makers on the other side—for more
information, see the main documents of the association
[6, 35]. The main goal is to translate knowledge from
studies at the bench side to care at the bedside by follow-
ing mechanism: from discovery to health application, to
evidence-based guidelines, to advanced health care ser-
vices and finally to health impacts for the patient [60, 61].
Information and communication technologies (ICT)
resulting in cost-effective modernisation of health care
A holistic presentation of individuals and discoursed
health condition by ICT approach implies a redesign of
health care services. The ICT support is the prerequisite
for an effective PPPM by disease modelling, individua-
lised patient profiles, optimised diagnostic and treatment
approaches. The ICT tools include mathematical model-
ling methods, such as probabilistic relational models and
process models, prediction of a disease development,
precise patient stratification, creation of the multimodal
diagnostic approaches, elaboration of the best possible
therapy algorithms, an estimation of individual outcomes,
distanced patient monitoring, advanced avatar technolo-
gies, and bid data management amongst others. Con-
textually, ICT is anticipated to result in profound and
cost-effective modernisation of health care benefiting
the patient, health care providers and society at large
[28, 29, 62–66].
The crucial role of multilevel diagnostics in PPPM
Accumulating evidence demonstrates that an ideal bio-
marker does not exist. The role of multilevel diagnostics
is to provide maximum clinically relevant information
by utilising pathology- and stage-specific biomarker
panels at the level of medical imaging, subcellular im-
aging, multi-omics and relevant hybrid technologies.
Integrating this information allows for targeted prevention
and personalised treatment regimes, avoiding unnecessary
drug toxicity, decreasing negative side-effects and redu-
cing morbidity [27–29, 62, 67–69].
Laboratory medicine in PPPM concepts: from passive
assistance to active advising
Delayed intervention, untargeted medication, overdosed
patients and ineffective treatments, amongst others, are
the deficits in currently pursued medical services that
demand a revised role of laboratory medicine in health
care systems. The laboratory services should become
more complex, advancing multifactorial analysis. Such a
complex analytics should result in recommendations
and active advising for clinicians in order to more accur-
ately interpret health-related data of the individual/patient.
Therefore, an effective ICT support (see the “Information
and communication technologies (ICT) resulting in
cost-effective modernisation of health care” section)
is mandatory. Practical implementation of novel and
complex laboratory tests certainly should be considered
from the viewpoint of their reasonability, cost-effectiveness
and value added to a data interpretation. Smart laboratory
investigation strategies and all-encompassing data interpret-
ation are essential for an appropriate relationship between
laboratory medicine and clinicians acting hand-
in-hand as the decision makers responsible for better
individual outcomes [70–75].
Well-regulated biobanking and biopreservation is pivotal
for future progress in PPPM
For the future progress in development of novel bio-
marker panels, predictive and prognostic technologies
and personalisation of treatment regimes, an internation-
ally valid biobanking and biopreservation are essential. A
proper creation of that is currently an ongoing process in
PPPM [66]. Considering individual types of biological
material (tissue, saliva, blood and cell samples, DNA,
RNA, proteins, metabolites, etc.), the major challenges
are due to:
– Consideration of ethical aspects including
privacy- and security-related issues [76, 77]
– Adequate national and international regulations
– Optimised protocols for collecting, storing and
retrieving the samples
– High analytical quality of all the process of
biobanking and biopreservation
– Adequately organised clinical/patient databases.
An effective support by the advanced ICT systems for
smoothly run processing and adequate data interpret-
ation is crucial for the clinical utility of biobanks [66].
Design of professional interactome in PPPM
PPPM carries highly multi- and interdisciplinary character
and demonstrates high level of international cooperation.
Consequently, related networking demands an effective
interaction amongst professional groups as well as be-
tween health care professionals and patient groups and
policy-makers. All these groups currently do “speak differ-
ent languages,” which may create some communication
barriers, however, reinforcing each group’s perspective to
reach higher level of understanding and cooperation in
PPPM framework. The specific output of this design
activity is the so-called professional interactome [78]. The
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PPPM-related interactome represents the most optimal
model of health care organisation with significantly in-
creased quality of multilevel communication and cooper-
ation resulting in improved individual patient outcomes
and health care economy (see the “Advanced business
models for PPPM concepts in health care” section).
Education as the heart of the PPPM-related scientific
excellence and successful practical implementation
The ultimate goal is to create a new culture in the health
care sector and to promote high level of professionalism
by new generations of healthcare-givers who will be cap-
able to implement an all-encompassing approach to
Table 1 Conclusions and expert recommendations
Term Advantages Limitations Optimal application and unique niche
Traditional,
complementary
and alternative
medicine, TCAM
Increases the own repair capacity
of the human body; deals with
natural products and physiological
approaches; is dedicated to disease
prevention and well-being; highly
effective at the level of suboptimal
health condition
Less effective for disease care; in
manifest pathologies can be applied
to complement conventional
treatments such as surgery,
chemo-therapy, etc.; cultural barriers
can exist when TCAM is introduced
by the country of origin to other
countries with sufficiently different
cultural habits
➢ Diagnosis and treatment of
suboptimal health conditions
➢ Cost-effective preventive medicine
➢ Emphasises well-being
➢ Pain management
➢ Complementary treatments
➢ Cultural traditions of the country
of origin
Person-centred
medicine, PCM
Promotion of health as a state of
physical, mental, social and spiritual
well-being; potential for disease
reduction; emphasis on science
and humanism; PCM promotes
approaches to health improvement,
respect and responsibility at
individual and community levels
Realisation of the ideals promoted
by PCM demands clear definitions
and validated strategies
➢ Health care philosophy
➢ Mental maturation of society at large
➢ Integration of sciences and humanism
➢ Promotion of health
➢ Promotion of respect and responsibility
in the society
Individualised
medicine, IM
IM propagates a holistic approach
by acknowledging multidimensional
interaction between internal and
external risk factors which vary from
individual to individual.
IM is clearly focused on
individualisation of standardised
intervention, but it provides less
developed concepts of predictive
and preventive medicine, if any.
➢ Holistic approach to standardised
intervention
➢ Patient categorisation and modelling
Stratified
medicine, SM
More targeted treatments according
to individual patient subtype;
stratified treatment algorithms
Although being an extremely
important instrument, SM represents
just one step towards “personalised
medicine.”
➢ Cohort subgrouping
➢ Patient stratification
Personalised
medicine, PM
Actually considered best possible
medical treatments adapted to the
needs of the patient
Concepts of PM are adapted to
“disease care” but not to “health
care.”
Semi-personalised medicine
compromising between standardisation
and individualisation in medicine
Precision medicine,
PrecMed
PrecMed attracts attention of
policy-makers to problems persisting
in medical services; additionally
released budgets in medical
sciences; increased publicity for
disease care; potentially increased
cooperation level between individual
medical fields
Politically motivated initiative
utilising advantages of already
existing and above listed
approaches; strong limitations by
selectively promoted technological
focuses (e.g. genomics); unclear
integration strategies in medicine;
unclear cost-effectiveness, benefits to
individual patient cohorts and overall
health care economy
➢ Potentially improved clinical impacts
of specific areas such as genomics
➢ Potential technological integration
in medical fields
➢ Potentially improved outcomes in
some patient cohorts
Predictive preventive
and personalised
medicine, PPPM
PPPM is a really complex
all-encompassing approach
combining advantages of the
above listed individual approaches
and minimising their specific
disadvantages; clear concepts
demonstrating the highest level of
maturity; the most optimal strategies
considering interests of healthy
individuals, subpopulations, patient
cohorts, health care systems and
society as a whole.
PPPPM is considered as the
“medicine of the future” which
needs the paradigm change for
entire spectrum of medical research
and services, improved professional
and general educational levels, new
economic and application models
for both disease and health care.
➢ Desirable versus current health care
systems
➢ Predictive medicine
➢ New spectrum of screening programmes
➢ Targeted prevention
➢ Currently unmet needs of healthy
subpopulations and patient cohorts
➢ Cost-effective medical services and
optimised health care economy
➢ New dimension of professional interests
➢ New scale of the knowledge integration
➢ Highly motivated technological innovation
➢ Highly motivated interdisciplinary and
multidisciplinary cooperation
➢ Individualised patient profiling
➢ Active participation of patients in the
health care process
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patient care recognising the complexity and individuality
of the human being. In order to promote innovative
educational programmes, the following worldwide pion-
eer initiatives have been developed:
– The EPMA Journal regularly updates information
about medical innovations and advanced health
care providing expert recommendations in
predictive diagnostics, targeted preventive
measures and individualised treatment algorithms
(https://epmajournal.biomedcentral.com/ and
http://www.springer.com/biomed/journal/13167).
– Advances in predictive, preventive and personalised
medicine (http://www.springer.com/series/10051):
this book series, launched in 2012, provides an
overview of complex strategies, innovative
technologies, novel biomarker panels, and
multidisciplinary aspects of advanced biomedical
approaches in individual PPPM areas and health
care as a whole. New technologies and guidelines
are provided for medical ethics, early and predictive
diagnostics, targeted prevention, treatments tailored
to the person, health care organisation and
economy. This book series is intended to serve as a
reference source for multidisciplinary research and
the health care industry with special emphasis on
advanced health promotion and cost-effective
treatment of diseases.
Advanced business models for PPPM concepts in health care
If left unchanged, a long-term poor cost-effectiveness
may lead to economic collapse of current health care
systems with persisting archaic business models. Across
Europe, there is a great diversity of systems, payment
models and reimbursement schemes in health care [72].
This imposes a highly fragmented market. On the one
hand, there is a need for policy dialogue in order to
achieve improved structure and delivery. On the other
hand, advanced business models are required, in order
to motivate
– Healthcare-givers to apply more individualised
diagnostic and treatment approaches
– Healthy individuals and patients to accept
greater responsibility towards their own health
condition
– Industry to create novel products for health support,
promotion and monitoring
– Policy-makers for smart long-term regulations in
health care sector such as an effective promotion of
increased health literacy in population, advanced
screening programmes and new reimbursement
models for individual subpopulations and
professional groups
– Finally, the society at large to reinvest budgets
focused on the most cost-effective health promotion
and primary health care.
In view of economic strain and the ageing populations,
PPPM-related innovation in health care systems is crit-
ical for keeping the high quality of health care affordable
and sustainable on European and global scale. Since its
very beginning, EPMA is systematically working on the
economy of PPPM that is pivotal for advancing health
care on European and global scale [6, 8, 20–22, 28, 30,
35, 37, 40, 71, 72, 79–82].
Conclusions and expert recommendations
Concluding remarks are summarised in Table 1 in form
of advantages and limitations listed for individual types
of medicines analysed in this paper followed by recom-
mendations for their most optimal application.
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